. 2017 Aug 16;2(8):872–881. doi: 10.1001/jamacardio.2017.1883

Table 2. Number of Events and Crude and Weighted Event Rates According to Treatment^a.

	Apixaban			Dabigatran			Rivaroxaban			Warfarin
	Events	Rate		Events	Rate		Events	Rate		Events	Rate
	Events	Crude	Weighted	Events	Crude	Weighted	Events	Crude	Weighted	Events	Crude	Weighted
1-y Follow-up
Ischemic stroke/SE	10	0.68	0.83	22	0.70	0.65	14	1.09	1.20	57	0.79	0.81
All-cause death	19	1.62	1.52	51	1.62	1.84	26	2.01	1.67	249	3.45	3.11
Any bleeding	8	0.68	0.57	23	0.74	0.73	17	1.33	1.38	109	1.52	1.53
Intracranial/gastrointestinal bleeding	<5	0.09	0.06	6	0.19	0.16	<5	0.23	0.29	39	0.54	0.54
2.5-y Follow-up
Ischemic stroke/SE	14	0.85	0.85	41	0.61	0.58	16	0.75	0.81	109	0.70	0.69
All-cause death	22	1.32	1.21	91	1.33	1.48	49	2.28	2.10	428	2.71	2.47
Any bleeding	11	0.67	0.56	44	0.65	0.65	22	1.04	1.09	202	1.30	1.31
Intracranial/gastrointestinal bleeding	<5	0.12	0.12	17	0.25	0.21	6	0.28	0.30	72	0.46	0.45

Abbreviations: IPTW, inverse probability of treatment weighed; SE, systemic embolism.

^{^a}

Crude rates are events divided by person time per 100 years; weighted rates are based on IPTW population and express population mean treatment rates per 100 years. Main analysis.

Table 2. Number of Events and Crude and Weighted Event Rates According to Treatmenta.

Table 2. Number of Events and Crude and Weighted Event Rates According to Treatment^a.